By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in the Czech Republic to Wegovy maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.

With the purchase of a plant in the Czech Republic, Novo Nordisk is saying “jak se máš” to hundreds of new employees—and expanding its production footprint along the way. | Novavax is selling its 150,

Novavax (NASDAQ:NVAX) is selling its manufacturing facility in the Czech Republic to Novo Nordisk (NVO) for $200M. The Gaithersburg, Maryland-based biotech has been grappling with lower sales of its only marketed product,

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy.

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that it has signed a definitive agreement to sell its

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil,

Novavax plans to sell its Czech Republic manufacturing site to a pharmaceutical giant. The deal stands to drive $200 million to the Gaithersburg vaccine maker.

Novavax Inc. shares climbed over 4% pre-market Wednesday following the announcement of a $200 million deal to sell its Bohumil, Czech Republic manufacturing facility to Novo Nordisk. The definitive agreement includes the transfer of a 150,